Skip to content
Study aid only. Verify against current guidelines before clinical use.
Step 2 CK · Internal Medicine · Endocrinology

Thyrotoxicosis Differential, Thyroiditis & Graves Orbitopathy

Overproducing, leaking, or imported — find the source, then treat it

Endocrinology·Thyroid·8 min read·9 high-yield points·Reviewed by Veli Bakalov, MD @HemeOncBuddy
Study materialsNo account needed
Card deckActive-recall cards · quick checks · quiz

Confirming thyrotoxicosis and finding the source

Two terms. Thyrotoxicosis is excess circulating thyroid hormone from any source; hyperthyroidism is the subset in which the gland itself overproduces. Only overproduction responds to synthesis blockers or radioiodine, so naming the mechanism is the whole game.

Biochemistry. A suppressed TSH with a high free T4 (usually with a high T3) confirms primary thyrotoxicosis. A high T3 with a normal free T4 (T3-toxicosis) is typical of early Graves disease and autonomous nodules. While the cause is sorted out, a β-blocker (propranolol, atenolol) controls tremor, palpitations, and tachycardia; diltiazem or verapamil substitutes when β-blockers are contraindicated.

Etiology. A thyrotoxic patient with a diffuse goiter and obvious orbitopathy needs no further proof of Graves disease. Otherwise, measure TSH-receptor antibodies (TRAb; the stimulating fraction is TSI): a positive result establishes Graves. If TRAb is negative or the picture is atypical (nodular gland, painful neck, recent iodine exposure), obtain a 24-hour radioactive iodine uptake (RAIU) and scan; radioiodine studies are avoided in pregnancy and lactation. Alternatives are Doppler ultrasound (high flow in Graves, low in destructive thyroiditis) and the total T3 (ng/dL) to T4 (μg/dL) ratio, where a value above 20 favors overproduction because an overactive gland releases proportionally more T3.

Radioiodine uptake and the cause of thyrotoxicosis
Cause24-h uptake / scanDistinguishing clues
Graves diseaseHigh, diffuseTRAb positive; diffuse goiter with bruit; orbitopathy, pretibial myxedema, acropachy
Toxic adenomaHigh in one nodule; rest of gland suppressedSingle palpable nodule; often T3-predominant
Toxic multinodular goiterPatchy hot and cold areasOlder patient with a nodular gland
Subacute thyroiditisNear zeroPainful, tender gland; fever; high ESR and CRP; recent viral illness
Painless or postpartum thyroiditisLowNontender; TPO antibodies; postpartum form within 12 months of delivery
Exogenous thyroid hormoneLowNo goiter; low serum thyroglobulin
Iodine loadLow (tracer diluted)Recent CT contrast, amiodarone, or kelp; high urine iodine
Struma ovariiLow in the neckPelvic uptake on whole-body scan
hCG-mediatedNot performed in pregnancyHyperemesis or molar pregnancy; TRAb negative

Graves disease. The most common cause of hyperthyroidism in iodine-sufficient regions, typically in women aged 20 to 50, with a diffusely enlarged, hypervascular gland.

Lid lag and a staring gaze reflect adrenergic overactivity and occur with any cause of thyrotoxicosis. Proptosis, pretibial myxedema, and thyroid acropachy are antibody-mediated and point specifically to Graves disease.

Thyroiditis and other low-uptake causes

Why uptake is low. In destructive thyroiditis, inflamed follicles spill stored T4, T3, and thyroglobulin into the blood. TSH falls, the damaged gland makes no new hormone, and it traps almost no radioiodine.

Subacute granulomatous (de Quervain) thyroiditis. Follows a viral upper respiratory infection: fever, malaise, and a firm, exquisitely tender goiter with pain radiating to the jaw or ear. ESR (often >50 mm/h) and CRP are high and RAIU is near zero; histology shows granulomas with multinucleated giant cells. Treat pain with NSAIDs; use prednisone (about 40 mg/day, tapered over several weeks) for severe pain or NSAID failure.

Painless (silent) and postpartum thyroiditis. Autoimmune lymphocytic variants related to Hashimoto thyroiditis. The postpartum form begins within 12 months of delivery or miscarriage, is more likely with TPO antibodies or type 1 diabetes, tends to recur with later pregnancies, and leaves a lasting risk of permanent hypothyroidism, so check TSH yearly. Positive TRAb and high Doppler flow instead suggest postpartum Graves; radioiodine testing is skipped in a nursing mother.

The three thyroiditis patterns that cause thyrotoxicosis
FeatureSubacute granulomatousPainless (silent)Postpartum
TriggerViral infectionAutoimmune (lymphocytic)Autoimmune; within 12 months of delivery or miscarriage
NeckPainful, very tenderPainless, small goiterPainless, small goiter
ESRMarkedly elevatedNormalNormal
TPO antibodiesUsually negativeOften positiveUsually positive
Specific therapyNSAIDs; prednisone if severeβ-blocker onlyβ-blocker only
Long termMost recover fullySome become hypothyroidRecurs; permanent hypothyroidism risk

Shared management. The thyrotoxic phase is leakage of preformed hormone, so thionamides (which block new synthesis) and radioiodine (which the gland cannot take up) are useless. Give a β-blocker only and recheck thyroid tests every 4–8 weeks to catch the next phase.

  1. Thyrotoxic phaseseveral weeks of hormone leak; β-blocker for symptoms
  2. Hypothyroid phaseweeks to months; temporary levothyroxine if symptomatic
  3. Recoverymost patients are euthyroid within about a year
  4. Follow-upa minority remain hypothyroid; check TSH periodically

Exogenous thyroid hormone. Factitious ingestion (weight loss, health-care workers) or excess prescribed levothyroxine gives low RAIU, no goiter, and a low serum thyroglobulin, because the gland is quiescent; thyroiditis raises thyroglobulin. Check anti-thyroglobulin antibodies too, since they interfere with the assay.

Iodine load (Jod-Basedow). Iodinated CT contrast, amiodarone, or kelp supplements give autonomous nodules the substrate to overproduce, especially in a nodular goiter from an iodine-deficient region. Uptake is low because the tracer is diluted in a large iodide pool; 24-hour urine iodine is high.

Struma ovarii. An ovarian teratoma composed mostly of thyroid tissue: low neck uptake, pelvic uptake on a whole-body scan, and cure by resection.

hCG-mediated thyrotoxicosis. hCG shares TSH's α-subunit and has a similar β-subunit, so it weakly stimulates the TSH receptor. Gestational transient thyrotoxicosis appears near the hCG peak at 10–12 weeks, often with hyperemesis gravidarum, without goiter or eye disease and with negative TRAb. It fades as hCG falls in the second trimester, so care is supportive (fluids, antiemetics, a brief β-blocker) without antithyroid drugs. Molar pregnancy and choriocarcinoma produce far more hCG and frank hyperthyroidism that resolves once the tumor is evacuated or treated.

Treating Graves disease

Thionamides. Every symptomatic patient also receives a β-blocker. Methimazole and propylthiouracil (PTU) inhibit thyroid peroxidase, blocking organification and coupling. Methimazole is preferred (once daily, less severe hepatotoxicity). A course runs about 12–18 months and is stopped if TRAb has normalized; relapse is common, especially with a large goiter, high TRAb, or continued smoking.

PTU niches. Methimazole is teratogenic in early pregnancy (aplasia cutis, choanal and esophageal atresia), so PTU is used in the first trimester and methimazole resumes afterward to limit PTU liver risk. PTU is also favored in thyroid storm because it additionally blocks peripheral T4→T3 conversion. In pregnancy, use the lowest dose that keeps free T4 at or just above the upper limit of normal, because thionamides cross the placenta and can cause fetal hypothyroidism.

Agranulocytosis (ANC <500/μL) usually strikes within the first 3 months of either thionamide. Fever or sore throat means stop the drug and obtain a CBC with differential; never switch to the other thionamide, because cross-reactivity is common. Get a baseline CBC and liver tests before starting.

Graves treatment options
OptionFavored whenAvoidKey risks
MethimazoleMost patients choosing drugs; active eye disease; after the first trimesterFirst trimesterAgranulocytosis, rash, cholestatic hepatitis, embryopathy
PTUFirst trimester; thyroid stormRoutine use (liver risk)Agranulocytosis, fulminant hepatic necrosis (boxed warning), ANCA vasculitis
Radioactive iodineRelapse after drugs; high surgical risk; no active eye diseasePregnancy, breastfeeding, conception within 6 months, active moderate–severe orbitopathy, suspicious noduleHypothyroidism (expected), worsening orbitopathy
ThyroidectomyLarge or compressive goiter, suspicious nodule, hyperparathyroidism, moderate–severe orbitopathy, pregnancy needing curePoor surgical candidatesHypocalcemia, recurrent laryngeal nerve palsy, lifelong levothyroxine

Radioactive iodine. Oral I-131 is concentrated by the overactive gland and destroys it over the following months. Confirm a negative pregnancy test and advise avoiding conception for about 6 months. Because RAI can trigger or worsen orbitopathy, particularly in smokers, give prophylactic oral prednisone with mild active eye disease and avoid RAI in active moderate–severe or sight-threatening disease. Hypothyroidism is the intended endpoint: check thyroid tests every 4–6 weeks and start levothyroxine when it appears.

Thyroidectomy. Near-total or total thyroidectomy suits the indications in the table; in pregnancy it is done in the second trimester. Prepare with methimazole to euthyroidism, a β-blocker, and potassium iodide (SSKI or Lugol solution) for about 10 days to shrink gland vascularity. Afterward, watch for hypocalcemia from parathyroid injury and hoarseness from recurrent laryngeal nerve injury, and start levothyroxine.

Graves orbitopathy

Pathogenesis. TRAb bind TSH receptors on orbital fibroblasts, which also signal through the IGF-1 receptor. Activated fibroblasts secrete hydrophilic glycosaminoglycans and differentiate into fat. Extraocular muscles enlarge in a fusiform pattern with tendon sparing on CT or MRI, the inferior rectus most often, then the medial rectus, causing restricted gaze and diplopia. Findings include proptosis, lid retraction, periorbital edema, conjunctival injection, and exposure keratitis. Eye disease can precede, accompany, or follow the hyperthyroidism.

Risk and course. Smoking is the strongest modifiable risk factor for onset, severity, and poor treatment response; radioiodine, uncontrolled thyroid function, and high TRAb also contribute. An active inflammatory phase (pain, redness, swelling; Clinical Activity Score ≥3 of 7) lasts months before burning out into inactive fibrosis.

  1. Every patientstop smoking; restore euthyroidism without overshooting into hypothyroidism; artificial tears and gel
  2. Mild diseaseselenium for 6 months, mainly where selenium intake is low; benefit is unproven in selenium-replete areas such as the US
  3. Active moderate–severeweekly IV methylprednisolone pulses, or teprotumumab
  4. Sight-threateninghigh-dose IV methylprednisolone; urgent orbital decompression if no response within 1–2 weeks
  5. Inactive with deformityrehabilitative surgery in order: decompression → strabismus → eyelid

Teprotumumab. A monoclonal antibody against the IGF-1 receptor that reduces proptosis and diplopia. Adverse effects include hyperglycemia, hearing loss, muscle cramps, flares of inflammatory bowel disease, and teratogenicity, so contraception is required.

Reduced acuity, color desaturation, a relative afferent pupillary defect, or field loss signals dysthyroid optic neuropathy from muscles crowding the orbital apex. Give high-dose IV methylprednisolone immediately and proceed to decompression if vision does not recover.